Pfizer, BioNTech's updated booster protects against Omicron in human trial

Pfizer, BioNTech's updated booster protects against Omicron in human trial Pfizer and its German partner BioNTech said their COVID-19 vaccine booster, adapted for the BA.4 and the BA.5 subvariants, generated a strong immune response and was well tolerated in testing on humans. Ludwig Burger,Manas Mishra Reuters

...

With the results, which the companies described as consistent with preclinical data, the partners are following up with human trial data that had previously been missing from their successful filings for regulatory approval. ...